SCHEMBL12907464

SCHEMBL12907464

Cc1n[nH]c2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGK1 O00141 2/20 0.51
LRRK2 Q5S007 3/20 0.46
DHFR P00374 1/20 0.46
PDPK1 O15530 2/20 0.45
TTK P33981 1/20 0.45
JAK2 O60674 4/20 0.45
FGFR1 P11362 1/20 0.43
FGFR2 P21802 1/20 0.43
FGFR3 P22607 1/20 0.43
MAP2K7 O14733 2/20 0.42
MAP2K4 P45985 2/20 0.42
TDO2 P48775 1/20 0.42
METAP2 P50579 1/20 0.42
JAK3 P52333 2/20 0.41
AAK1 Q2M2I8 1/20 0.41
CDC7 O00311 1/20 0.41
PLK4 O00444 1/20 0.41
DAPK3 O43293 1/20 0.41
DYRK3 O43781 1/20 0.41
ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12907444 0.87 TTK (0.54) SGK1LRRK2PDPK1TTKJAK2
SCHEMBL12907430 0.85 JAK2 (0.63) SGK1PDPK1TTKJAK2FGFR1
SCHEMBL12907131 0.85 JAK2 (0.62) SGK1DHFRPDPK1JAK2JAK3
SCHEMBL18148589 0.81 JAK2 (0.51) SGK1LRRK2DHFRPDPK1TTK
SCHEMBL14397096 0.80 PDPK1 (0.53) SGK1PDPK1JAK2FGFR1FGFR2
SCHEMBL14061660 0.80 LRRK2 (0.44) SGK1LRRK2DHFRPDPK1TTK
SCHEMBL12907457 0.79 JAK2 (0.67) PDPK1TTKJAK2FGFR1FGFR2
SCHEMBL12907451 0.78 FGFR1 (0.70) SGK1PDPK1JAK2FGFR1FGFR2
SCHEMBL14061443 0.77 METAP2 (0.49) LRRK2DHFRJAK2FGFR1TDO2
SCHEMBL12907471 0.76 AAK1 (0.57) PDPK1JAK2FGFR1FGFR2FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed